Aegea Biotechnologies, Inc. and Tauriga Sciences Inc. Announce Progress on the Development of Rapid, Lateral Flow Point-of-Care COVID-19 Diagnostic Test  Additionally—Initial Prototypes of the Portable, Disposable Devices for the Lateral Flow COVID-19 Test Have Been Produced NEW YORK, NY and SAN DIEGO, CA, July 28, 2020 (GLOBE NEWSWIRE) -- via...

Aegea Biotechnologies, Inc. Announces the Issuance of 7 Additional Key U.S. Patents Relating to its Core, Next Generation Nucleic Acid Clinical Diagnostic Technologies and COVID-19 Test Development NEW YORK, NY and SAN DIEGO, CA, May 18, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE ‒ Aegea Biotechnologies, Inc. ( “Aegea”) ( www.aegeabiotech.com), a biotechnology company focusing on the...

Aegea Biotechnologies, Inc. Expands its Platforms for Novel Coronavirus (COVID-19) Testing under the Collaboration Agreement with Tauriga Sciences, Inc. NEW YORK, NY and SAN DIEGO, CA, April 20, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – As previously announced, Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga”) and Aegea Biotechnologies, Inc....